LEAH Labs - also doing business as Lifengine Animal Health Laboratories Incorporated - is structured around addressing companion animal medicine with living therapies. With a particular focus on dogs, principals of the firm are addressing a pressing need in canine oncology care - building a high-impact, model system to accelerate novel human cell therapy development in spontaneous disease in dogs. LEAH is described as the first company to use gene editing to build solutions for disease in companion animals with an initial product focus being to translate the success of CAR-T cells against blood malignancies in humans to our furry best friends.
